PTC Therapeutics Aktie
68,04
EUR
-0,72
EUR
-1,05
%
78,92
USD
+0,49
USD
+0,62
%
PTC Therapeutics jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Werbung
PTC Therapeutics Aktie Analyse
| 29.01.18 | PTC Therapeutics Sector Perform | RBC Capital Markets | |
| 29.09.17 | PTC Therapeutics Equal weight | Barclays Capital | |
| 29.09.17 | PTC Therapeutics Sector Perform | RBC Capital Markets | |
| 16.03.17 | PTC Therapeutics Sector Perform | RBC Capital Markets | |
| 03.03.17 | PTC Therapeutics Equal weight | Barclays Capital | |
| 11.11.16 | PTC Therapeutics Sector Perform | RBC Capital Markets | |
| 01.03.16 | PTC Therapeutics Neutral | Wedbush Morgan Securities Inc. | |
| 01.03.16 | PTC Therapeutics Sector Perform | RBC Capital Markets | |
|
Werbung
|
|||
| 24.02.16 | PTC Therapeutics Sector Perform | RBC Capital Markets | |
| 05.05.15 | PTC Therapeutics Neutral | ROTH Capital Partners, LLC | |
Werbung
Werbung